This may be an important consideration in the design of new drug therapy regimens that aim to minimize the detrimental effects of long-term HAART in HIV-1-infected patients. The authors would like to express their gratitude to all of the patients who participated in the TORO 1 and TORO 2 studies, as well as to the numerous Roche and Trimeris study personnel who have worked

on these trials. We would also like to acknowledge the other members of the TORO 1 and TORO 2 study teams: Belinda Atkins, Silvia find more Bader-Weder, MD, Laurence Bourdeau, PhD, Neil E. Buss, PhD, Bonaventura Clotet, MD, PhD, Calvin Cohen, MD, MSc, Jean-François Delfraissy, MD, Ralph DeMasi, PhD, Lucille Donatacci, MS, Claude Drobnes, MD, Joseph J. Eron, Jr, MD, Fiona Hughes, BSc, Christine Katlama, MD, Tosca Kinchelow, MD, Daniel Kuritzkes, MD, Emily Labriola-Tomkins, BA, Jacob Lalezari, MD, Joep Lange, MD, PhD, Adriano Lazzarin, MD, Julio Montaner, MD, Christopher Natale, MSc, Peter Piliero, MD, Miklos P. Salgo, MD, PhD, Anna Shikhman, BSN, MBA, Lynn Smiley, MD, Hans-Jürgen Stellbrink, MD, Benoit Trottier, MD, Adeline Valentine, MSc, Sharon Walmsley, MD, Cynthia Wat, MBBS and Martin Wilkinson, MSC. These studies were supported by F. Hoffmann-La Roche Ltd, Basel, Switzerland and Trimeris,

Inc., Morrisville, Epigenetics inhibitor NC, USA. Under the guidance of the lead author,

Caudex Medical created the initial draft of this manuscript. “
“Background. This study assesses, for the first time, the incidence, etiology, and determinants associated with traveler’s diarrhea (TD) among French forces deployed to N’Djamena, Chad. Methods. A prospective study was conducted based on physician consultation for diarrhea during a 5-month French forces mandate. Diarrhea was defined as ≥3 loose stools in a 24-hour period or ≥2 loose stools within the last 8 hours. For each diarrheic episode, an anonymous from physician-administered questionnaire was completed and a stool sample collected. Samples were tested for parasites, bacteria, and enteric viruses. Global incidence rate was calculated using the mean number of soldiers based in N’Djamena (n = 1,024) over the 5-month period, as denominator. Incidence rates were also estimated for each of the eleven 2-week periods of stay. A case-crossover analysis estimated determinants associated with diarrhea. Results. A total of 240 cases of diarrhea were notified by military physicians, resulting in a global incidence rate of 49 cases per 1,000 person-months (PM). The cumulative individual risk of developing diarrhea during the study period was 0.23. The incidence per 2-week stay began at 8.8/1,000 PM, rose to 54.4/1,000 PM after 1 month, and decreased after 2 months.